References
1. National Research Council. Indoor Pollutants. Committee on Indoor Pollutants, Board on Toxicology and Environmental Health Hazards, Assembly of Life Sciences, National Research Council. Washington, DC:National Academy Press, 1981.
2. Lewtas J. Airborne carcinogens. Pharmacol Toxicol 72 (S1):55-63 (1993).
3. Wallace LA, Pellizzari ED. Personal air exposures and breath concentrations of benzene and other volatile hydrocarbons for smokers and nonsmokers. Toxicol Lett 35:113-116 (1986).
4. Samet JM. Radon and lung cancer. J Natl Cancer Inst 81(10):745-757 (1989).
5. Bierma TJ. Radon risk factors: evaluating the health implications of home exposures. J Environ Health 51(5):277-281 (1989).
6. Nero AV. Estimated risk of lung cancer from exposure to radon decay products in U.S. homes: a brief review. Atmos Environ 22(10): x2205-2211 (1988).
7. Humble CG, Samet JM, Pathak DR. Marriage to a smoker and lung cancer risk. Am J Public Health 77(5):598-602 (1987).
8. Eriksen MP, LeMaistre CA, Newell GR. Health hazards of passive smoking. Annu Rev Public Health 9:47-70 (1988).
9. Saracci R, Riboli E. Passive smoking and lung cancer: current evidence and ongoing studies at the International Agency for Research on Cancer. Mutat Res 222:117-127 (1989).
10. Wu-Williams AH, Samet JM. Environmental tobacco smoke: exposure-response relationships in epidemiologic studies. Risk Anal 10(1):39-48 (1990).
11. Chesebro MJ. Passive smoking. Am Fam Physican 37(5):212-218 (1988)
12. Friedman GD, Petitti DB, Bawol RD. Prevalence and correlates of passive smoking. Am J Public Health 73(4):401-405 (1983).
13. Vainio H, Partanen T. Population burden of lung cancer due to environmental tobacco smoke. Mutat Res 222:137-140 (1989).
14. Paxman DG, Robinson JC. Regulation of occupational carcinogens under OSHA's air contaminants standard. Regul Toxicol Pharmacol 12:296-308 (1990).
15. National Research Council. Issues in risk assessment: use of the maximum tolerated dose in animal bioassays for carcinogenicity. Washington, DC:National Academy Press, 1993.
16. McConnell EE. The maximum tolerated dose: the debate. J Am College Toxicol 8(6): 1115-1120 (1989).
17. Clayson DB, Iverson F, Mueller R. An application of the maximum tolerated dose: an inadequately precise decision point in designing a carcinogenesis bioassay? Teratogen Carcinogen Mutagen 11:279-296 (1991).
18. Clayson DB, Clegg DJ. Classification of carcinogens: polemics, pedantics, or progress. Regul Toxicol Pharmacol 14:147-166 (1991).
19. Ennever FK, Noonan TJ, Rosenkranz HS. The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis 2:73-78 (1987).
20. Gregory AR. Species comparisons in evaluating carcinogenicity in humans. Regul Toxicol Pharmacol 8:160-190 (1988).
21. Munro A. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? Adverse Drug React Toxicol Rev 12(1):5-34 (1993).
22. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249:970-971 (1990).
23. Ames BN, Gold LS. Animal cancer tests and cancer prevention. J Natl Cancer Inst Monogr 12: 125-132 (1992).
24. Lave LB, Ennever FK, Rosenkranz HS, Omenn GS. Information value of the rodent bioassay. Nature 336:631-633 (1988).
25. Tomatis L, Aitio A, Wilbourn J, Shuker L. Human carcinogens so far identified. Jpn J Cancer Res 80:795-807 (1989).
26. Abelson PH. Testing for carcinogens with rodents [editorial]. Science 249:1357 (1990).
27. Goodman G, Wilson R. Predicting the carcinogenicity of chemicals in humans from rodent bioassay data. Environ Health Perspect 94:195-218 (1991).
28. Ashby J, Morrod RS. Detection of human carcinogens. Nature 352:185-186 (1991).
29. Cohen SM, Ellwein LB. Cell proliferation and carcinogenesis. Science 249:1007-1011 (1990).
30. Trosko JE. Towards understanding carcinogenic hazards: a crisis in paradigms. J Am Coll Toxicol 8(6):1121-1132 (1989).
31. Clayson DB. Can a mechanistic rationale be provided for non-genotoxic carcinogens identified in rodent bioassays? Mutat Res 221:53-67 (1989).
32. Butterworth BE. Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutat Res 239:117-132 (1990).
33. Clayson DB. Bladder carcinogenesis in rats and mice: possibility of artifacts. J Natl Cancer Inst 52(6):1685-1689 (1974).
34. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 50:7415-7421 (1990).
35. Preston-Martin S, Pike MC, Ross RK, Henderson BE. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. In: Chemically Induced Cell Proliferation: Implications for Risk Assessment (Butterworth BE, Slaga TJ, Farland W, McClain M, eds). New York:Wiley-Liss, 1991;21-34.
36. Imlay JA, Linn S. DNA damage and oxygen radical toxicity. Science 240:1302-1309 (1988).
37. Hertz-Picciotto I, Gravitz N, Neutra R. How do cancer risks predicted from animal bioassays compare with the epidemiologic evidence? The case of ethylene dibromide. Risk Anal 8(2):205-214 (1988).
38. Gold LS, Manley NB, Ames BN. Extrapolation of carcinogenicity between species: qualitative and quantitative factors. Risk Anal 12(4): 579-588 (1992).
39. Wartenberg D, Simon R. Comment: Integrating epidemiologic data into risk assessment. Am J Public Health 85(4):491-493 (1995).
40. Haseman JK, Lockhart AM. Correlations between chemically related site-specific carcinogenic effects in long-term studies in rats and mice. Environ Health Perspect 101:50-54 (1993).
41. Allen B, Crump K, Shipp A. Correlation between carcinogenic potency of chemicals in animals and humans. Risk Anal 8:531-544 (1988).
42. Shore R, Iyer V, Altshuler B, Pasternack B. Use of human data in quantitative risk assessment of carcinogens: impact on epidemiologic practice and the regulatory process. Regul Toxicol Pharmacol 15:180-221 (1992).
43. Berry CL. Pesticides. Hum Toxicol 7:433-436 (1988).
44. Portier C. Species correlation of chemical carcinogens. Risk Anal 8:551-553 (1988).
45. Reznik-Schuller H, Reznik G. Experimental pulmonary carcinogenesis. Int Rev Exp Pathol 20:211-281 (1979).
46. Warheit DB. Interspecies comparisons of lung responses to inhaled particles and gases. CRC Crit Rev Toxicol 20(1):1-29 (1989).
47. Lippmann M, Schlesinger RB. Interspecies comparisons of particle deposition and mucociliary clearance in tracheobronchial airways. J Toxicol Environ Health 13(1):441-469 (1984).
48. Hernandez JA, Anderson AE Jr, Holmes WL, Foraker AG. Pulmonary parenchymal defects in dogs following prolonged cigarette smoke exposure. Am Rev Respir Dis 93(1):78-83 (1966).
49. Rockey EE, Speer FD. The ill effects of cigarette smoking in dogs. Int Surg 46(6):520-530 (1966).
50. Zwicker FM, Filipy RE, Park JF, Loscutoff SM, Ragan HA, Stevens DL. Clinical and pathological effects of cigarette smoke exposure in beagle dogs. Arch Pathol Lab Med 102:623-628 (1978).
51. Hammond EC, Auerbach O, Kirman D, Garfinkel L. Effects of cigarette smoking on dogs: I. Design of experiment, mortality, and findings in lung parenchyma. Arch Environ Health 21:740-753 (1970).
52. Cross FT, Palmer RF, Filipy RE, Dagle DE, Stuart BO. Carcinogenic effect of radon daughters, uranium ore dust and cigarette smoke in beagle dogs. Health Phys 42(1):33-52 (1982).
53. Will JA. An overview of alternatives. Lab Anim 14:37-41 (1985).
54. Glickman LT, Domanski LM. An alternative to laboratory animal experimentation for human health risk assessment: epidemiological studies of pet animals. Altern Lab Anim 13:267-285 (1986).
55. Mausner JS, Kramer S. Mausner & Bahn Epidemiology: An Introductory Text. Phila-delphia, PA:WB Saunders Co., 1985.
56. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. New York:Van Nostrand Reinhold, 1982.
57. Schlesselman JJ. Case-Control Studies. New York:Oxford University Press, 1982.
58. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA:Little, Brown, and Co., 1987.
59. Rothman KJ. Modern Epidemiology. Boston, MA:Little, Brown and Co., 1986.
60. Kelsey JL, Thompson WD, Evans AS. Methods in Observational Epidemiology. New York: Oxford University Press, 1986.
61. Austin H, Hill HA, Flanders WD, Greenberg RS. Limitations in the application of case-control methodology. Epidemiol Rev 16(1):65-76 (1994).
62. Last JM, ed. A Dictionary of Epidemiology. New York:Oxford University Press, 1983.
63. Feinstein AR, Horwitz RI. Double standards, scientific methods, and epidemiologic research. N Engl J Med 307(26):1611-1617 (1982).
64. Gray-Donald K, Kramer MS. Causality inference in observational vs. experimental studies. An empirical comparison. Am J Epidemiol 127(5): 885-892 (1988).
65. Taubes G. Epidemiology faces its limits. Science 269:164-169 (1995).
66. Neuberger JS. Residential radon exposure and lung cancer: an overview of ongoing studies. Health Phys 63(5):503-509 (1992).
67. Letourneau EG, Krewski D, Choi NW, Goddard MJ, McGregor RG, Zielinski JM, Du J. Case-control study of residential radon and lung cancer in Winnipeg, Manitoba, Canada. Am J Epidemiol 140:310-322 (1994).
68. Lubin JH, Samet JM, Weinberg C. Design issues of epidemiologic studies of indoor exposure to Rn and risk of lung cancer. Health Phys 99(6):807-817 (1990).
69. Samet JM, Stolwijk J, Rose SL. Summary: International Workshop on Residential Radon Epidemiology. Health Phys 60(2):223-227 (1991).
70. Dalager NA, Pickle LW, Mason TJ, Correa P, Fontham E, Stemhagen A, Buffler PA, Ziegler RG, Fraumeni JF. The relation of passive smoking to lung cancer. Cancer Res 46:4808-4811 (1986).
71. Woodward A, McMichael AJ. Passive smoking and cancer risk: the nature and uses of epidemiological evidence. Eur J Cancer 27(11): 1472-1479 (1991).
72. Stockwell HG, Goldman AL, Lyman GH, Noss CI, Armstrong AW, Pinkham PA, Candelora EC, Brusa MR. Environmental tobacco smoke and lung cancer risk in nonsmoking women. J Natl Cancer Inst 84: 1417-1422 (1992).
73. Pershagen G, Hrubec Z, Svensson, C. Passive smoking and lung cancer in Swedish women. Am J Epidemiol 125(1):17-24 (1987).
74. Akiba S, Kato H, Blot WJ. Passive smoking and lung cancer among Japanese women. Cancer Res 46:4804-4807 (1986).
75. Muir-Gray JA, Millard DW, Walton J. Passive smoking in the workplace--nuisance or risk? Statement of the Green-College Consensus Conference. Community Med 9(3):209-215 (1987).
76. Kabat GC, Stellman SD, Wynder EL. Relation between exposure to environmental tobacco smoke and lung cancer in lifetime nonsmokers. Am J Epidemiol 142:141-148 (1995).
77. Doll R, Peto R. The Causes of Cancer. Oxford: Oxford University Press, 1981.
78. Landrigan PJ, Markowitz S. Current magnitude of occupational disease in the United States. Estimates from New York State. In: Occupational Health in the 1990s: Developing a Platform for Disease Prevention (Landrigan PJ, Selikoff IJ, eds). New York:New York Academy of Sciences, 1989;27-45.
79. Swanson GM. Cancer prevention in the workplace and natural environment. Cancer 62: 1725-1746 (1988).
80. Schottenfeld D. Chronic disease in the workplace and environment: cancer. Arch Environ Health 39(3):150-157 (1984).
81. National Research Council. Animals as Sentinels of Environmental Health Hazards. Washington, DC:National Academy Press, 1991.
82. Buck WB. Animals as monitors of environmental quality. Vet Hum Toxicol 21:277-284 (1979).
83. Ragland WL, Gorham JR. Tonsilar carcinoma in rural dogs. Nature 214:925-926 (1967).
84. Reif JS, Cohen D. Retrospective radiographic analysis of pulmonary disease in rural and urban dogs. Arch Environ Health 20:684-689 (1970).
85. Reif JS, Cohen D. The environmental distribution of canine respiratory tract neoplasms. Arch Environ Health 22:136-140 (1971).
86. Hayes HM Jr, Hoover R, Tarone RE. Bladder cancer in pet dogs: a sentinel for environmental cancer? Am J Epidemiol 114(2):229-233 (1981).
87. Harbison ML, Godleski JJ. Malignant mesothelioma in urban dogs. Vet Pathol 20:531-540 (1983).
88. Glickman LT, Domanski LM, Maguire TG, Dubielzig RR, Churg A. Mesothelioma in pet dogs associated with exposure of their owners to asbestos. Environ Res 32:305-313 (1983).
89. Glickman LT, Shofer FS, McKee LJ, Reif JS, Goldschmidt MH. Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogs. J Toxicol Environ Health 28:407-414 (1989).
90. Hayes HM, Tarone RE, Casey HW, Huxsoll DL. Excess of seminomas observed in Vietnam service U.S. military working dogs. J Natl Cancer Inst 82:1042-1046 (1990).
91. Hayes HM, Tarone RE, Cantor KP, Jessen CR, McCurnin DM, Richardson RC. Case-control study of canine malignant lymphoma: positive association with dog owner's use of 2,4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 83:1226-1231 (1991).
92. Reif JS, Dunn K, Ogilvie GK, Harris CK. Passive smoking and canine lung cancer risk. Am J Epidemiol 135(3):234-239 (1992).
93. Reif JS, Lower KS, Ogilvie GK. Residential exposure to magnetic fields and risk of canine lymphoma. Am J Epidemiol 141:352-359 (1995).
94. Cole P. The evolving case-control study. J Chron Dis 32:15-27 (1979).
95. Schuster NH. Pulmonary asbestosis in a dog. J Pathol Bacteriol 34:751-757 (1931).
96. Schneider R. Comparison of age, sex, and incidence rates in human and canine breast cancer. Cancer 26:419-426 (1970).
97. Hayes HM. The comparative epidemiology of selected neoplasms between dogs, cats and humans. A review. Eur J Cancer 00:1299-1308 (1978).
98. Shofer FS, Sonnenschein EG, Goldschmidt MH, Laster LL, Glickman LT. Histopathology and dietary prognostic factors for canine mammary carcinoma. Breast Cancer Res Treat 13: 49-60 (1989).
99. Sonnenschein EG, Glickman LT, Goldschmidt MH, McKee LJ. Body conformation, diet, and breast cancer in dogs: a case-control study. Am J Epidemiol 133:694-703 (1991).
100. Brodey RS. The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine osteosarcoma. Yale J Biol Med 52:345-361 (1979).
101. Tjalma RA. Canine bone sarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst 36:1137-1150 (1966).
102. Hayes HM. Canine bladder cancer: epidemiologic features. Am J Epidemiol 104(6):673-677 (1976).
103. Hayes HM, Wilson GP. Comparative aspects of nasal passage carcinoma in dogs with man. In: Nasal Tumors in Animals and Man (Reznik G, Stinson SF, eds). Boca Raton, FL:CRC Press, 1983.
104. Thomas CW, Rising JL, Moore JK. Blood lead concentrations of children and dogs from 83 Illinois families. J Am Vet Med 169(11): 1237-1240 (1976).
105. Kucera E. Dogs as indicators of urban lead distribution. Environ Monit Assess 10:51-57 (1988).
106. Reynolds PM, Reif JS, Ramsdell HS, Tessari JD. Canine exposure to herbicide-treated lawns and urinary excretion of 2,4-dichlorophenoxyacetic acid. Cancer Epidemiol Biomarkers Prev 33:233-237 (1994).
107. Lillienfeld DE, Gallo MA. 2,4-D, 2,4,5-T, and 2,3,7,8-TCDD: an overview. Epidemiol Rev 11:28-58 (1989).
108. Dorn CR, Taylor DON, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40:307-318 (1968).
109. MacVean DW, Monlux AW, Anderson PS, Silberg SL, Roszell JF. Frequency of canine and feline tumors in a defined population. Vet Pathol 15:700-715 (1978).
110. Monsein DL. An overview of animal cancer registries in the United States and suggestions for improved applications. Compendium on Continuing Education for the Practicing Veterinarian 13(7):1139-1146 (1991).
111. Sternberg SS. Canine malignant lymphoma and 2,4-dichlorophenoxyacetic acid herbicides [letter]. J Natl Cancer Inst 84:271 (1992).
112. Carlo GL, Cole P, Miller AB, Munro IC, Solomon KR, Squire RA. Review of a study reporting an association between 2,4-dichlorophenoxyacetic acid and canine malignant lymphoma: report of an expert panel. Regul Toxicol Pharmacol 16:245-252 (1992).
Last Update: December 9, 1997